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Abstract
Background: Addition of glutamine to enteral nutrition formulas is consistently associated with a
significant decrease in septic morbidity in critically ill patients, possibly related to the attenuation
of gut dysfunction. This pilot study was undertaken to compare the effects of enteral administration
of two glutamine-enriched formulas containing either additional free glutamine or glutamine-rich
proteins, with a standard solution on plasma and mucosal concentrations of glutamine in patients
admitted in the Department of Intensive Care.
Methods: Following randomization, glutamine concentration was determined in endoscopically
sampled duodenal biopsies and plasma, before and after a 7-day period of continuous
administration of the designated solution.
Results: The mucosal concentration of glutamine increased in the duodenal biopsies sampled from
patients randomized to the solution containing the glutamine-rich proteins (from 3.6 ± 2.2 to 6.7
± 5.2 micro-mol/g protein), but not from the others. There were no differences between the 3
groups in the plasma concentrations of glutamine, which remained stable over time.
Conclusion:  The source of supplemental glutamine can influence gut mucosal glutamine
concentrations, suggesting differences in its availability or utilization.
Background
Addition of glutamine to the nutritional support provided
to critically ill patients has been suggested, namely to pre-
vent gut dysfunction and subsequent multiple organ fail-
ure. The beneficial effects of glutamine supplementation
to critically ill patients have been shown in at least two
controlled studies [1,2], where patients randomized to a
glutamine-enriched regimen had improved long-term sur-
vival [1] and reduced septic morbidity [2]. Although
incompletely elucidated, the beneficial effects of these
enriched solutions may have been related to the intestinal
effects of glutamine. Reported intestinal effects of
glutamine include the maintenance of gut barrier func-
tion, intestinal cell proliferation and differentiation,
increased DNA and protein content and synthesis, and
decreased production of pro-inflammatory cytokines [3–
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9]. The intestinal extraction rate of glutamine is higher
than other amino acids [10,11].
The enteral route is preferred for nutritional support in
critically ill patients [12]. In addition, the gut barrier func-
tion is better preserved when glutamine is supplied on the
apical rather than the basolateral side of the enterocyte
[13]. Therefore, the enrichment of the glutamine content
of enteral feeding solutions is a logical and attractive ther-
apeutic approach. New feeding formulas including sup-
plemental glutamine (13–15 g/L) have been marketed
recently. Glutamine is added in its free (unbound) form
immediately before use of the solution, or is already
present in the vegetal proteins incorporated in the
solution.
This pilot study compared the effects of these solutions on
the gut and plasma concentrations of glutamine, in order
to select one for future studies on gut functional
parameters.
Methods
This prospective, randomized, single-blind, placebo-con-
trolled, pilot study enrolled adult patients referred to the
Department of Intensive Care of the Erasme University
Hospital. The hospital ethic's committee approved the
study and signed consent was obtained from the patients'
next-of-kin. The inclusion criteria consisted of a loss of
consciousness and a reasonable expectation of at least 7-
days' requirement for nutritional support and survival.
Exclusion criteria consisted of any contra-indication to
naso-gastric tubing, eso-gastro-duodenal endoscopy, duo-
denal biopsy (prothrombin time < 60% and/or platelet
count < 100,000/mm3) or the absence of signed informed
consent.
At the time of inclusion, primary diagnosis and usual
demographic parameters were recorded. Arterial blood
samples were drawn at inclusion, centrifuged (3000 rpm
for 10 min) and stored (-80°C) for the determination of
plasma glutamine concentration. After intravenous infu-
sion of butylscopolamine (40 mg), an oeso-gastro-duode-
nal endoscopy was performed (Olympus, PCF10, Tokyo,
Japan), and 8 duodenal biopsies were sampled. The sam-
ples were kept in dry tubes at -80°C.
Patients were then randomized using a computerized ran-
dom number table and sealed envelopes to receive the
control solution (Nutrison Standard®, Nutricia, Bornem,
Belgium), the free glutamine-enriched solution (Alitraq®,
Ross-Abbott, Columbus, OH), or the solution containing
glutamine from wheat-derived proteins (Stresson®, Nutri-
cia, Bornem, Belgium). The solutions were kindly pro-
vided by their respective manufacturers. The composition
of the solutions is detailed in the table 1.
The solutions were continuously administered at a rate of
30 mL/h (720 mL/day) from day 0 to day 1, and at a rate
of 60 mL/h (1440 mL/day) from day 1 to day 7, using a
peristaltic pump. Gastric residues were checked once daily
and the administration was interrupted for 4 hours if it
was higher than 300 mL, and a pro-kinetic agent (Cis-
apride, Prepulsid®, Janssen, Beerse, Belgium) was then
prescribed. In the case of diarrhea, the administration rate
was slowed by half and an anti-diarrheal medication
(Loperamide, Imodium®, Janssen) was administered. The
patients were dropped from the study if they recovered the
ability to eat before the end of the 7-day period. Plasma
and duodenal samples were taken on day 7, four hours
after administration of the feeding solution was stopped.
Patient outcome was followed until ICU discharge.
For determination of plasma glutamine, blood was centri-
fuged (3000 rpm for 10 minutes) and the plasma was
stored at -70°C. The duodenal biopsies were immediately
frozen at -70°C. Once defrosted, the duodenal tissue was
homogenized. Determination of glutamine concentration
by selected ion monitoring quantification by gas chroma-
tography/mass spectrometry (GCMS), using HFBA-
glutamine [14].
Statistical analysis included an analysis of variance for
repeated measures and a Student's t-test for comparison of
the biochemical parameters between day 7 and baseline.
A p value < 0.05 was considered as significant. Results are
expressed as mean ± standard deviation (SD).
Results
This study was performed over an 8-month period. A total
of 12 patients were eligible, of whom two died and one
recovered the ability to eat during the study period. The
characteristics of the 9 remaining patients are shown in
Table 2. Mean age was 57 ± 11 years.
Over the 7-day study period, the patients actually received
80–90% of the prescribed amount of their designated
solution, i.e., Nutrison Standard (7600 ± 2447 mL), Ali-
Table 1: Composition of the formulas
Per 100 mL Nutrison 
Standard
AlitraQ Stresson
Caloric density (kcal) 100 100 125
Proteins (g) 4 5.25 7.5
Fat (g) 3.90 1.55 4.17
Carbohydrates (g) 12.3 16.5 14.5
Protein-bound glutamine (g) 0.40 0 1.30
Total glutamine content (g) 0.40 1.54 1.30Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/13
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traQ (8430 ± 217 mL), or Stresson (8433 ± 1100 mL). The
total amounts of glutamine received were 30.4 ± 9.8 g,
129.8 ± 3.3 g and 109.6 ± 15.4 g for Nutrison Standard,
AlitraQ and Stresson, respectively.
Plasma glutamine concentrations (Fig 1, upper panel)
increased slightly from 322 ± 84 µmol/L at baseline to 389
± 134 µmol/L (NS). There was no significant difference in
the time course of the plasma glutamine concentration
between the groups.
In each patient randomized to "Stresson", mucosal
glutamine concentrations increased to reach 1.3–2.0
times the baseline value at the end of the 7-day period.
Hence, the values of mucosal concentrations of glutamine
increased from 3.86 ± 1.37 to 4.71 ± 3.25 µmol/g protein
in the "Stresson" group. There was no change in the other
groups (Fig 1, lower panel).
Discussion
This pilot study suggests that the mucosal glutamine con-
centration was increased after administration of an enteral
feeding solution containing glutamine-rich proteins but
not additional free glutamine.
The duodenal samples were taken approximately 20–30
cm distally to the tip of the naso-gastric catheter, as in a
previous study of enteral glutamine absorption in volun-
teers [15]. The discontinuation of the administration of
the enteral solution four hours before the second duode-
nal sampling may represent a limitation to the interpreta-
tion of the results. However, this delay was the shortest
possible to allow appropriate viewing and sampling of a
duodenal biopsy, especially in this patient population in
whom gastric emptying is often delayed.
Three studies have investigated the effects of glutamine-
enriched enteral solutions in critically ill patients
[2,16,17]. The solutions used in these studies were
enriched with free glutamine. In the two studies using Ali-
traQ [2,16], as in the present one, the plasma concentra-
tions of glutamine in the samples drawn were not
increased after 7 days, probably because glutamine is
rapidly metabolized. The baseline glutamine concentra-
tions measured in the present study were in the same
range as previously reported in critically ill patients
[2,16,18]. In volunteers, the peak post-absorptive plasma
glutamine concentration was higher after ingestion of
glutamine in its free form than protein-bound [19], while
the splanchnic extraction was similar [10]. In contrast, our
data indicate that the mucosal concentration of glutamine
can be influenced by the source of glutamine. However,
an increase in the mucosal concentration may indicate an
enhanced availability or a reduced utilization of
glutamine, but provides no information about the con-
centration of glutamine in different cell types. Impor-
tantly, the absorption of peptides can be better than that
of free amino-acids [20].
A limitation of this pilot study lies on the small size of the
study population, which does not allow statistical analy-
sis. However, these data could be of interest for the selec-
tion of an enteral formula for future studies on the effects
of glutamine on gut physiology.
In conclusion, the data presented here suggest that the
source of glutamine in enteral formulas can influence its
metabolism. Further studies are required to assess
whether this can translate into an improvement in intesti-
nal function and a clinical benefit.
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Table 2: Characteristics of the patients
Age Formula Gender Diagnosis at the time of admission ICU Outcome
1 52 NTS F Meningo-encephalitis – Cerebral aneurysm Deceased
2 75 NTS M Spontaneous intracerebral hemorrhage Survived
3 49 NTS M Post-anoxic encephalopathy Survived
4 62 ALI F Subarachnoid hemorrhage Survived
5 49 ALI F Subarachnoid hemorrhage Survived
6 37 ALI F Spontaneous intracerebral hemorrhage Survived
7 55 STR F Cerebral trauma Survived
8 64 STR F Post-surgical cerebral hemorrhage Survived
9 67 STR F Subarachnoid hemorrhage SurvivedNutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/13
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Concentrations of glutamine (mean ± SD) in samples drawn from patients randomized to Nutrison Standard (broken line, dia- monds), Alitraq (dotted line, squares) or Stresson (continuous line, triangles) Figure 1
Concentrations of glutamine (mean ± SD) in samples drawn from patients randomized to Nutrison Standard (broken line, dia-
monds), Alitraq (dotted line, squares) or Stresson (continuous line, triangles). The samples were taken before (day 0) and after 
(day 7) administration of the designated formula.
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